Deutsche Bank Reiterates “Buy” Rating for AstraZeneca (AZN)

Deutsche Bank restated their buy rating on shares of AstraZeneca (LON:AZN) in a report published on Monday. The brokerage currently has a GBX 6,900 ($90.16) price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on AZN. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on AstraZeneca and gave the company a sell rating in a report on Thursday, February 14th. Credit Suisse Group set a GBX 6,350 ($82.97) target price on AstraZeneca and gave the company a buy rating in a report on Friday, February 15th. Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a report on Thursday, February 14th. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) target price on AstraZeneca and gave the company a buy rating in a report on Thursday, February 14th. Finally, Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a report on Friday, December 7th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. AstraZeneca currently has an average rating of Buy and a consensus target price of GBX 6,222.20 ($81.30).

Shares of AZN stock opened at GBX 6,096 ($79.66) on Monday. AstraZeneca has a fifty-two week low of GBX 4,260 ($55.66) and a fifty-two week high of GBX 5,520 ($72.13).

The company also recently declared a dividend, which will be paid on Wednesday, March 27th. Stockholders of record on Thursday, February 28th will be paid a GBX 146.80 ($1.92) dividend. This represents a dividend yield of 2.57%. This is a boost from AstraZeneca’s previous dividend of $68.40. The ex-dividend date is Thursday, February 28th.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What is a Swap?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply